Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation.
about
Pharmacodynamic modeling of adverse effects of anti-cancer drug treatmentModeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety AssessmentThe role of concentration-effect relationships in the assessment of QTc interval prolongationEarly QT assessment--how can our confidence in the data be improved?Single Doses up to 800 mg of E-52862 Do Not Prolong the QTc Interval--A Retrospective Validation by Pharmacokinetic-Pharmacodynamic Modelling of Electrocardiography Data Utilising the Effects of a Meal on QTc to Demonstrate ECG Assay SensitivityInvestigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data.Systems ChronotherapeuticsDrug-induced QT interval prolongation: mechanisms and clinical managementInteraction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information.QTc interval prolongation in HIV-infected patients: a case-control study by 24-hour Holter ECG recording.Losmapimod concentration-QT relationship in healthy volunteers: meta-analysis of data from six clinical trials.Model-based evaluation of drug-induced QTc prolongation for compounds in early development.Evaluating the Use of Linear Mixed-Effect Models for Inference of the Concentration-QTc Slope Estimate as a Surrogate for a Biological QTc Model.Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects.Population pharmacokinetic/pharmacodynamic modeling of guanfacine effects on QTc and heart rate in pediatric patients.Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans.Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk managementAge and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case study.Focus on ziprasidone: a review of its use in child and adolescent psychiatryDrug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.The use of clinical utility assessments in early clinical developmentIdentifying the translational gap in the evaluation of drug-induced QTc interval prolongation.Cardiovascular Safety Assessment in Early-Phase Clinical Studies: A Meta-Analytical Comparison of Exposure-Response Models.From pharmacokinetics to therapeutics.CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.Influence of Meals and Glycemic Changes on QT Interval Dynamics.Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers.Translating QT interval prolongation from conscious dogs to humans.Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.Modelling PK/QT relationships from Phase I dose-escalation trials for drug combinations and developing quantitative risk assessments of clinically relevant QT prolongations.Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.Model-Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion.How do we assess whether the QT interval is abnormal: myths, formulae and fixed opinion.Blood concentrations are better predictors of chioroquine poisoning severity than plasma concentrations: a prospective study with modeling of the concentration/effect relationships.Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval.Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects.Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.Balancing the Need for Personalization of QT Correction and Generalization of Study Results: Going Beyond Thorough QT Studies.Integrated TK-TD modeling for drug-induced concurrent tachycardia and QT changes in beagle dogs.
P2860
Q26766318-67E92236-369C-4FDD-B467-CD756C9E5BBAQ26801610-22C57A94-D5B2-4DB4-81CC-BD5D7CF35321Q26866417-18A000CC-B3B0-42E9-B473-FB9754DCA9C7Q27020964-A9A3753C-1EF2-489C-AA82-BFD03EE011D6Q28547388-3605FFF1-5E15-498B-B419-DB0C8AD64BCCQ31145263-1CDFB094-C39B-42DD-8774-1E1B00B6B899Q33573675-D472AD0F-DCF7-4722-875D-436DCB68B215Q33949538-2B31532D-C856-42CA-B5B7-F6A918729FF7Q34116212-ADD955AD-D8D9-4FF2-9D76-C2A7C20C65A3Q34520166-DA21349B-E3B0-4C9C-AEA2-6DFE8A528F81Q34550452-E1A096FC-63C6-4C70-92A4-066B4EA5A420Q34953730-FD17AE1A-9371-4A49-9B9D-D1A0574004B8Q35110110-F3F1F69D-0DAF-41F5-AED9-8EC1EDC94183Q35142403-3CE53C5F-9DF5-4589-A291-2012A6FE564DQ35318113-4D39B52F-46C3-495E-8A2E-3A5AEC8DE880Q36400366-09AF1951-C401-492F-A8B1-1F0D69D46C24Q36439198-01FBA968-BE9C-40B0-B609-5830BBCDEB68Q36688587-38BAEE18-D23F-4D8D-B051-EEDAC7706D95Q36974977-6164E1A5-4821-4CDA-8CC2-32B217D8E106Q36987981-DC0EFB27-8914-4399-B913-F208E008C2A1Q37038099-DC8B68E3-DCB5-4179-8040-7441995C0E10Q37149087-882D2953-2D16-4C01-A3D8-70B9BF4205CCQ37369309-80715824-D764-4893-A128-8A5AB522878FQ37461720-48DC9BBE-DAF8-4344-AF3C-76E9C9F8F770Q37550564-A02475AC-8A87-489C-AD22-33528FF30281Q38239777-3758CE69-ED59-4522-B9F8-2E72390F1B48Q38679113-3C53D788-30B0-4B06-8BD4-5889D5969C7CQ38684764-00538A4C-FC1D-4F59-B78F-D2E59C7F919BQ39404396-55D2E09E-9685-4562-B77C-032A74D980E5Q39461781-2C6C8582-70A1-485B-86A9-EC95DE5D32BFQ39908884-E539BD62-AC12-4B85-A410-466850293B9BQ39959170-62A97F28-AF0A-415B-9EA7-C3EF882F5E7BQ41066240-36A1FBE2-C067-47AE-8BFD-16609511F754Q41391365-55977277-C54D-4456-A492-E06B49D4430AQ41934443-CB68D107-DA57-41DD-B2AF-A3CBF94B5481Q42694744-7148DA75-328F-49FD-8D5C-EC1CB6B9CF8FQ46587405-B84C7C26-2733-4DB2-A43E-4935D3F5E1FAQ46686425-AAC0C17A-9BF8-4412-A97B-680810A0877DQ48197901-CFFBCE6D-C60A-4F4D-908F-E72A8520ECA0Q48232888-92F15244-1FFB-49B8-B9AD-0690E5FE5F30
P2860
Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacokinetic-pharmacodynami ...... g-induced QT/QTc prolongation.
@ast
Pharmacokinetic-pharmacodynami ...... g-induced QT/QTc prolongation.
@en
type
label
Pharmacokinetic-pharmacodynami ...... g-induced QT/QTc prolongation.
@ast
Pharmacokinetic-pharmacodynami ...... g-induced QT/QTc prolongation.
@en
prefLabel
Pharmacokinetic-pharmacodynami ...... g-induced QT/QTc prolongation.
@ast
Pharmacokinetic-pharmacodynami ...... g-induced QT/QTc prolongation.
@en
P2860
P356
P1433
P1476
Pharmacokinetic-pharmacodynami ...... g-induced QT/QTc prolongation.
@en
P2093
Vladimir Piotrovsky
P2860
P2888
P304
P356
10.1208/AAPSJ070363
P407
P577
2005-10-24T00:00:00Z
P5875
P6179
1036020779